CRIS Current Research Information System

IELASI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.253
NA - Nord America 1.689
EU - Europa 973
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 106
SA - Sud America 89
OC - Oceania 2
Totale 5.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.637
VN - Vietnam 707
CN - Cina 546
SG - Singapore 537
IT - Italia 351
HK - Hong Kong 152
DE - Germania 135
SE - Svezia 86
KR - Corea 73
GB - Regno Unito 69
IN - India 62
NL - Olanda 59
BR - Brasile 52
FI - Finlandia 48
IE - Irlanda 48
FR - Francia 43
BD - Bangladesh 42
TG - Togo 38
CA - Canada 30
JP - Giappone 30
RU - Federazione Russa 28
AT - Austria 26
ZA - Sudafrica 19
AR - Argentina 18
PH - Filippine 17
ID - Indonesia 16
SC - Seychelles 14
MX - Messico 11
TH - Thailandia 11
BG - Bulgaria 10
CH - Svizzera 9
PK - Pakistan 9
CI - Costa d'Avorio 8
ES - Italia 8
TR - Turchia 8
LT - Lituania 7
NG - Nigeria 7
PL - Polonia 7
UA - Ucraina 7
EC - Ecuador 6
HR - Croazia 6
IQ - Iraq 6
MA - Marocco 6
BE - Belgio 5
JO - Giordania 5
MK - Macedonia 5
TW - Taiwan 5
CR - Costa Rica 4
DZ - Algeria 4
PS - Palestinian Territory 4
VE - Venezuela 4
CL - Cile 3
CZ - Repubblica Ceca 3
EE - Estonia 3
MY - Malesia 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
HU - Ungheria 2
IR - Iran 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TN - Tunisia 2
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
CM - Camerun 1
CO - Colombia 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
HN - Honduras 1
KE - Kenya 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MR - Mauritania 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
SV - El Salvador 1
SX - ???statistics.table.value.countryCode.SX??? 1
TV - Tuvalu 1
VC - Saint Vincent e Grenadine 1
Totale 5.113
Salva come PNG Salva come JPEG
Città #
Singapore 381
Ashburn 252
Ho Chi Minh City 203
Hanoi 185
Hefei 157
San Jose 141
Hong Kong 135
Bologna 101
Chandler 78
Santa Clara 78
Fairfield 66
Seoul 62
Boardman 55
Council Bluffs 55
Los Angeles 55
Dallas 53
Beijing 51
New York 50
Southend 50
Dublin 48
Helsinki 38
Lomé 38
Da Nang 35
Milan 30
Princeton 30
Munich 26
Haiphong 25
Houston 25
Rome 25
Tokyo 24
Lauterbourg 23
Frankfurt am Main 22
Dong Ket 21
Wilmington 21
Vienna 20
Woodbridge 19
Orem 17
Amsterdam 16
Seattle 15
Bengaluru 14
Cambridge 14
Redondo Beach 14
Guangzhou 13
Johannesburg 13
Ann Arbor 12
Buffalo 12
Chicago 11
Hải Dương 11
Jakarta 11
Phoenix 11
San Francisco 11
Falkenstein 10
Nuremberg 10
Sofia 10
Des Moines 9
Falls Church 9
San Giovanni in Persiceto 9
Thái Nguyên 9
Toronto 9
Abidjan 8
Berlin 8
Brooklyn 8
Can Tho 8
Shanghai 8
Shenzhen 8
Bern 7
London 7
Nanjing 7
San Diego 7
São Paulo 7
Abeokuta 6
Denver 6
Florence 6
Lahore 6
Montreal 6
Ninh Bình 6
Shenyang 6
Turin 6
Washington 6
Amman 5
Atlanta 5
Biên Hòa 5
Ha Long 5
Lappeenranta 5
Naples 5
San José 5
Skopje 5
Tongling 5
Turku 5
Verona 5
Warsaw 5
Westminster 5
Bremen 4
Brussels 4
Bắc Giang 4
Bắc Ninh 4
Bến Tre 4
Chennai 4
Columbus 4
Genoa 4
Totale 3.182
Salva come PNG Salva come JPEG
Nome #
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 262
Anabolic Androgenic Steroids and Hepatocellular Adenoma and Carcinoma: Molecular Mechanisms and Clinical Implications 229
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 229
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 214
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 203
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 196
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 192
Donafenib in hepatocellular carcinoma 191
Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia 181
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 178
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 167
TKIs in combination with immunotherapy for hepatocellular carcinoma 166
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 161
Natural history of hypovascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced mr imaging in cirrhotic patients during surveillance program 160
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 159
Treatment of combined hepatocellular and cholangiocarcinoma 156
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 156
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 155
Experience with regorafenib in the treatment of hepatocellular carcinoma 154
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 152
A case of Leishmania infection with focal splanchnic involvement without systemic symptoms: a potential anti-inflammatory role for vitamin D 129
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 125
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 124
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery 124
Lenvatinib mesylate to treat hepatocellular carcinoma 123
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 122
Hot topics in hepatocellular carcinoma 118
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 118
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 108
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 107
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 96
An update on atezolizumab for hepatocellular carcinoma 96
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma 92
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 81
Totale 5.224
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.172
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.172
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022303 0 0 19 8 29 18 8 35 22 13 105 46
2022/2023358 26 54 13 39 40 27 32 19 61 5 9 33
2023/2024210 7 26 14 14 39 43 10 13 14 10 12 8
2024/2025948 36 65 73 75 106 34 111 37 29 64 76 242
2025/20262.829 242 219 169 159 195 75 541 126 563 196 133 211
2026/2027305 158 116 31 0 0 0 0 0 0 0 0 0
Totale 5.224